IL106624A - Asanthin-converted xanthines, their preparation and pharmaceutical preparations containing them - Google Patents

Asanthin-converted xanthines, their preparation and pharmaceutical preparations containing them

Info

Publication number
IL106624A
IL106624A IL10662493A IL10662493A IL106624A IL 106624 A IL106624 A IL 106624A IL 10662493 A IL10662493 A IL 10662493A IL 10662493 A IL10662493 A IL 10662493A IL 106624 A IL106624 A IL 106624A
Authority
IL
Israel
Prior art keywords
denotes
alkyl
group
optionally
substituted
Prior art date
Application number
IL10662493A
Other languages
English (en)
Hebrew (he)
Other versions
IL106624A0 (en
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of IL106624A0 publication Critical patent/IL106624A0/xx
Publication of IL106624A publication Critical patent/IL106624A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL10662493A 1992-08-10 1993-08-09 Asanthin-converted xanthines, their preparation and pharmaceutical preparations containing them IL106624A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4226371 1992-08-10
DE4238423 1992-11-13

Publications (2)

Publication Number Publication Date
IL106624A0 IL106624A0 (en) 1993-12-08
IL106624A true IL106624A (en) 1999-01-26

Family

ID=25917371

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10662493A IL106624A (en) 1992-08-10 1993-08-09 Asanthin-converted xanthines, their preparation and pharmaceutical preparations containing them

Country Status (21)

Country Link
US (1) US5719279A (US20050026921A1-20050203-C00071.png)
EP (1) EP0654033A1 (US20050026921A1-20050203-C00071.png)
JP (1) JPH08500344A (US20050026921A1-20050203-C00071.png)
KR (1) KR950702988A (US20050026921A1-20050203-C00071.png)
CN (1) CN1043348C (US20050026921A1-20050203-C00071.png)
AU (1) AU681348B2 (US20050026921A1-20050203-C00071.png)
BG (1) BG62618B1 (US20050026921A1-20050203-C00071.png)
CA (1) CA2140883A1 (US20050026921A1-20050203-C00071.png)
CZ (1) CZ286459B6 (US20050026921A1-20050203-C00071.png)
FI (1) FI950542A0 (US20050026921A1-20050203-C00071.png)
HU (1) HUT65734A (US20050026921A1-20050203-C00071.png)
IL (1) IL106624A (US20050026921A1-20050203-C00071.png)
MX (1) MX9304819A (US20050026921A1-20050203-C00071.png)
NZ (1) NZ254804A (US20050026921A1-20050203-C00071.png)
PL (1) PL176389B1 (US20050026921A1-20050203-C00071.png)
RU (1) RU2138500C1 (US20050026921A1-20050203-C00071.png)
SG (1) SG55038A1 (US20050026921A1-20050203-C00071.png)
SK (1) SK18595A3 (US20050026921A1-20050203-C00071.png)
TW (1) TW252044B (US20050026921A1-20050203-C00071.png)
UA (1) UA46697C2 (US20050026921A1-20050203-C00071.png)
WO (1) WO1994003456A1 (US20050026921A1-20050203-C00071.png)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW252044B (US20050026921A1-20050203-C00071.png) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
WO1994025462A1 (en) * 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
DE4316576A1 (de) * 1993-05-18 1994-11-24 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
GB9415529D0 (en) 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE69531506T2 (de) * 1994-12-13 2004-06-24 Euroceltique S.A. Arylthioxanthine
ATE247655T1 (de) 1994-12-13 2003-09-15 Euro Celtique Sa Dreifachsubstituierte thioxanthine
US5864037A (en) * 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
US5786360A (en) * 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
WO1999031101A1 (en) * 1997-12-17 1999-06-24 University Of South Florida Adenosine receptor antagonists with improved bioactivity
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU4980999A (en) 1998-07-10 2000-02-01 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The A3 adenosine receptor antagonists
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
SI1230243T1 (sl) * 1999-11-12 2009-08-31 Biogen Idec Inc Policikloalkilpurini kot antagonisti adenozinskega receptorja
BR0015540A (pt) 1999-11-12 2002-07-23 Biogen Inc Antagonistas do receptor de adenosina e métodos de preparação e uso dos mesmos
DE60018216T2 (de) * 1999-12-24 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Kondensierte purinderivate
WO2001051490A1 (en) 2000-01-14 2001-07-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methanocarba cycloalkyl nucleoside analogues
EA007485B1 (ru) * 2001-02-24 2006-10-27 Берингер Ингельхайм Фарма Гмбх Унд Ко. Кг Производные ксантина, способ их получения, фармацевтическая композиция на их основе и способ ее получения
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
WO2004009091A1 (en) 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
EP1601649A4 (en) * 2003-02-19 2009-03-04 Endacea Inc A1-adenosine receptor antagonistic
RU2367442C2 (ru) 2003-04-25 2009-09-20 Новокардия, Инк. Способ нормализации мочеиспускания при нарушении функции почек
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
EP1636230A4 (en) * 2003-06-09 2010-06-16 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10355304A1 (de) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP2057160A1 (en) * 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
US9522916B2 (en) 2007-12-21 2016-12-20 Constance Neely Wilson A1 adenosine receptor antagonists
US7928259B2 (en) * 2008-02-12 2011-04-19 Frx Polymers, Inc. Diaryl alkylphosphonates and methods for preparing same
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX2011001525A (es) * 2008-08-15 2011-03-29 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
JP5334511B2 (ja) * 2008-09-22 2013-11-06 日本精化株式会社 化粧料
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AU2010228902A1 (en) * 2009-03-26 2011-10-06 Mapi Pharma Limited Process for the preparation of alogliptin
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
WO2011068978A1 (en) 2009-12-02 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
CN102971005A (zh) 2010-06-24 2013-03-13 贝林格尔.英格海姆国际有限公司 糖尿病治疗
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
RU2643336C1 (ru) * 2016-10-03 2018-01-31 Общество с Ограниченной Ответственностью "Компания "ЭЛТА" СРЕДСТВО, ПРОЯВЛЯЮЩЕЕ АНТИТРОМБОТИЧЕСКИЙ ЭФФЕКТ ПОСРЕДСТВОМ БЛОКИРОВАНИЯ РЕЦЕПТОРОВ ТРОМБОЦИТОВ ГП IIb-IIIa (ВАРИАНТЫ)
CN109796453A (zh) * 2019-02-12 2019-05-24 南京纽邦生物科技有限公司 一种1,7-二甲基黄嘌呤的制备方法
WO2022079245A1 (en) 2020-10-15 2022-04-21 Rheinische-Friedrich-Wilhelms-Universität Bonn 3-substituted xanthine derivatives as mrgprx4 receptor modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5032593A (en) * 1988-07-01 1991-07-16 Marion Merrell Dow Inc. Method of treating bronchoconstriction with 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
ATE176470T1 (de) * 1990-10-18 1999-02-15 Kyowa Hakko Kogyo Kk Xanthinderivate
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
TW252044B (US20050026921A1-20050203-C00071.png) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5366977A (en) * 1992-09-29 1994-11-22 The United States Of America, As Represented By The Department Of Health And Human Services Method of treating cystic fibrosis using 8-cyclopentyl-1,3-dipropylxanthine or xanthine amino congeners

Also Published As

Publication number Publication date
SG55038A1 (en) 1998-12-21
FI950542A (fi) 1995-02-08
WO1994003456A1 (de) 1994-02-17
CZ286459B6 (en) 2000-04-12
CA2140883A1 (en) 1994-02-17
RU95109100A (ru) 1996-12-27
KR950702988A (ko) 1995-08-23
AU4707193A (en) 1994-03-03
MX9304819A (es) 1994-02-28
PL307397A1 (en) 1995-05-15
JPH08500344A (ja) 1996-01-16
HUT65734A (en) 1994-07-28
BG99489A (bg) 1996-01-31
CZ34895A3 (en) 1995-10-18
UA46697C2 (uk) 2002-06-17
CN1086818A (zh) 1994-05-18
TW252044B (US20050026921A1-20050203-C00071.png) 1995-07-21
RU2138500C1 (ru) 1999-09-27
CN1043348C (zh) 1999-05-12
BG62618B1 (bg) 2000-03-31
IL106624A0 (en) 1993-12-08
SK18595A3 (en) 1995-07-11
US5719279A (en) 1998-02-17
AU681348B2 (en) 1997-08-28
EP0654033A1 (de) 1995-05-24
HU9302302D0 (en) 1993-10-28
PL176389B1 (pl) 1999-05-31
FI950542A0 (fi) 1995-02-08
NZ254804A (en) 1997-01-29

Similar Documents

Publication Publication Date Title
IL106624A (en) Asanthin-converted xanthines, their preparation and pharmaceutical preparations containing them
AU683270B2 (en) Novel chemical compounds having PDE-IV inhibition activity
RU2269529C2 (ru) Производные 8-хинолинксантина и 8-изохинолинксантина в качестве ингибиторов фосфоэстеразы pde 5
KR101564233B1 (ko) 푸리닐 유도체 및 칼륨 채널 조절제로서의 이의 용도
US6187780B1 (en) Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
AU2001273921A1 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
JP2000503005A (ja) ピロロピリミジンおよびその製造法
JP2003506375A (ja) チロシンタンパク質キナーゼｓｙｋのプリン誘導体阻害剤
JP2003505461A (ja) ８−フェニル−６，９−ジヒドロ−［１，２，４］トリアゾロ［３，４−ｉ］プリン−５−オン誘導体
JPS626555B2 (US20050026921A1-20050203-C00071.png)
WO1999062905A1 (en) 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
CA2328264A1 (en) Novel asymmetrically substituted xanthine derivatives, method for producing them and their use as medicaments with an adenosine-antagonistic effect
JP3020281B2 (ja) 新規なトリアゾロプリン類、その調製方法及び医薬組成物としての使用
DE4325254A1 (de) Unsymmetrisch substituierte Xanthine
US6919337B2 (en) 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
US6248746B1 (en) 3-(arylalkyl) xanthines
CA2327395C (en) New imidazotriazolopyrimidines, processes for preparing them and their use as pharmaceutical compositions
JPS635392B2 (US20050026921A1-20050203-C00071.png)
CA2242097C (en) Imidazotriazolopyrimidines, process for preparing them and their use as pharmaceutical compositions
US7361661B2 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
RH1 Patent not in force